249 related articles for article (PubMed ID: 24388482)
81. Positron Emission Tomography-Based Assessment of Metabolic Tumor Volume Predicts Survival after Autologous Hematopoietic Cell Transplantation for Hodgkin Lymphoma.
Procházka V; Gawande RS; Cayci Z; Froelich JW; Cao Q; Wilke C; Dusenbery K; Weisdorf DJ; Bachanova V
Biol Blood Marrow Transplant; 2018 Jan; 24(1):64-70. PubMed ID: 28942016
[TBL] [Abstract][Full Text] [Related]
82. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma.
Munshi PN; Hamadani M; Kumar A; Dreger P; Friedberg JW; Dreyling M; Kahl B; Jerkeman M; Kharfan-Dabaja MA; Locke FL; Shadman M; Hill BT; Ahmed S; Herrera AF; Sauter CS; Bachanova V; Ghosh N; Lunning M; Kenkre VP; Aljurf M; Wang M; Maddocks KJ; Leonard JP; Kamdar M; Phillips T; Cashen AF; Inwards DJ; Sureda A; Cohen JB; Smith SM; Carlo-Stella C; Savani B; Robinson SP; Fenske TS
Transplant Cell Ther; 2021 Sep; 27(9):720-728. PubMed ID: 34452722
[TBL] [Abstract][Full Text] [Related]
83. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Saxe DF; Maly JJ; Blum KA; Grover NS; Mathews SP; Gordon MJ; Danilov AV; Epperla N; Fenske TS; Hamadani M; Park SI; Flowers CR; Cohen JB
Cancer; 2018 Jun; 124(11):2306-2315. PubMed ID: 29579328
[TBL] [Abstract][Full Text] [Related]
84. Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission.
Chakhachiro ZI; Saliba RM; Okoroji GJ; Korbling M; Alousi AM; Betul O; Anderlini P; Ciurea SO; Popat U; Champlin R; Samuels BI; Medeiros LJ; Bueso-Ramos C; Khouri IF
Cancer; 2013 Sep; 119(18):3318-25. PubMed ID: 23775587
[TBL] [Abstract][Full Text] [Related]
85. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
[TBL] [Abstract][Full Text] [Related]
86. Diagnostic and Clinical Impact of Staging
Albano D; Ferro P; Bosio G; Fallanca F; Re A; Tucci A; Maria Ferreri AJ; Angelillo P; Gianolli L; Giubbini R; Bertagna F
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e457-e464. PubMed ID: 31129112
[TBL] [Abstract][Full Text] [Related]
87. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia.
Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Zhao XY; Han W; Zhang XH; Wang Y; Zhang YY; Qin YZ; Liu YR; Huang XJ
J Hematol Oncol; 2012 Jun; 5():29. PubMed ID: 22682059
[TBL] [Abstract][Full Text] [Related]
88. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma.
Kasamon YL; Jones RJ; Diehl LF; Nayer H; Borowitz MJ; Garrett-Mayer E; Ambinder RF; Abrams RA; Zhang Z; Flinn IW
Biol Blood Marrow Transplant; 2005 Jan; 11(1):39-46. PubMed ID: 15625543
[TBL] [Abstract][Full Text] [Related]
89. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2017 Aug; 92(8):806-813. PubMed ID: 28699667
[TBL] [Abstract][Full Text] [Related]
90. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma.
Evens AM; Winter JN; Hou N; Nelson BP; Rademaker A; Patton D; Singhal S; Frankfurt O; Tallman MS; Rosen ST; Mehta J; Gordon LI
Br J Haematol; 2008 Feb; 140(4):385-93. PubMed ID: 18162124
[TBL] [Abstract][Full Text] [Related]
91. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT.
Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I
Bone Marrow Transplant; 2013 Nov; 48(12):1530-6. PubMed ID: 23749108
[TBL] [Abstract][Full Text] [Related]
92. Outcomes of hematopoietic cell transplantation for transformed follicular lymphoma.
Ida H; Inamoto Y; Fukuhara S; Maeshima AM; Takeda W; Hirakawa T; Kuno M; Aoki J; Tanaka T; Ito A; Kim SW; Izutsu K; Fukuda T
Hematol Oncol; 2021 Dec; 39(5):650-657. PubMed ID: 34431557
[TBL] [Abstract][Full Text] [Related]
93. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
[TBL] [Abstract][Full Text] [Related]
94. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
Hermine O; Hoster E; Walewski J; Bosly A; Stilgenbauer S; Thieblemont C; Szymczyk M; Bouabdallah R; Kneba M; Hallek M; Salles G; Feugier P; Ribrag V; Birkmann J; Forstpointner R; Haioun C; Hänel M; Casasnovas RO; Finke J; Peter N; Bouabdallah K; Sebban C; Fischer T; Dührsen U; Metzner B; Maschmeyer G; Kanz L; Schmidt C; Delarue R; Brousse N; Klapper W; Macintyre E; Delfau-Larue MH; Pott C; Hiddemann W; Unterhalt M; Dreyling M;
Lancet; 2016 Aug; 388(10044):565-75. PubMed ID: 27313086
[TBL] [Abstract][Full Text] [Related]
95. Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
Epperla N; Fenske TS; Lazarus HM; Hamadani M
Bone Marrow Transplant; 2015 Nov; 50(11):1393-404. PubMed ID: 26281033
[TBL] [Abstract][Full Text] [Related]
96. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.
Epperla N; Ahn KW; Litovich C; Ahmed S; Battiwalla M; Cohen JB; Dahi P; Farhadfar N; Farooq U; Freytes CO; Ghosh N; Haverkos B; Herrera A; Hertzberg M; Hildebrandt G; Inwards D; Kharfan-Dabaja MA; Khimani F; Lazarus H; Lazaryan A; Lekakis L; Murthy H; Nathan S; Nishihori T; Pawarode A; Prestidge T; Ramakrishnan P; Rezvani AR; Romee R; Shah NN; Sureda A; Fenske TS; Hamadani M
J Hematol Oncol; 2019 Jan; 12(1):6. PubMed ID: 30630534
[TBL] [Abstract][Full Text] [Related]
97. Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation.
Haen SP; Groh C; Schumm M; Backert L; Löffler MW; Federmann B; Faul C; Dörfel D; Vogel W; Handgretinger R; Kanz L; Bethge WA
Ann Hematol; 2017 May; 96(5):817-827. PubMed ID: 28247058
[TBL] [Abstract][Full Text] [Related]
98. Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma.
Lambert JR; Bomanji JB; Peggs KS; Thomson KJ; Chakraverty RK; Fielding AK; Kottaridis PD; Roughton M; Morris EC; Goldstone AH; Linch DC; Ell PJ; Mackinnon S
Blood; 2010 Apr; 115(14):2763-8. PubMed ID: 20124510
[TBL] [Abstract][Full Text] [Related]
99. Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma.
Riedell PA; Hamadani M; Ahn KW; Litovich C; Murthy GSG; Locke FL; Brunstein CG; Merryman RW; Stiff PJ; Pawarode A; Nishihori T; Kharfan-Dabaja MA; Herrera AF; Sauter CS; Smith SM
Transplant Cell Ther; 2021 Nov; 27(11):911.e1-911.e7. PubMed ID: 34450333
[TBL] [Abstract][Full Text] [Related]
100. Prognostic value of pre-transplantation total metabolic tumor volume on
Sugio T; Baba S; Mori Y; Yoshimoto G; Kamesaki K; Takashima S; Urata S; Shima T; Miyawaki K; Kikushige Y; Kunisaki Y; Numata A; Takenaka K; Iawasaki H; Miyamoto T; Ishigami K; Akashi K; Kato K
Int J Hematol; 2022 Oct; 116(4):603-611. PubMed ID: 35701707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
